325 related articles for article (PubMed ID: 28642818)
1. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.
Sandoval-Sus JD; Mogollon-Duffo F; Patel A; Visweshwar N; Laber DA; Kim R; Jagal MV
J Immunother Cancer; 2017; 5():49. PubMed ID: 28642818
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy.
Colak R; Kapar C; Gulturk I; Yilmaz M
J Oncol Pharm Pract; 2024 Apr; 30(3):589-593. PubMed ID: 38111303
[TBL] [Abstract][Full Text] [Related]
3. Relapsed nodular lymphocyte-predominant Hodgkin lymphoma presenting as severe paraneoplastic hepatitis: a case report.
Deacon AJ; Goetz NN; Weber N; Clouston A; Gonsalkorala E; Baskerville C; Leggett B
J Med Case Rep; 2023 Jun; 17(1):269. PubMed ID: 37386640
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.
Foran AE; Nadel HR; Lee AF; Savage KJ; Deyell RJ
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e263-e266. PubMed ID: 27841828
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
Zhao L; Yang Y; Li W; Li T; Gao Q
Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.
Tardy MP; Gastaud L; Boscagli A; Peyrade F; Gallamini A; Thyss A
Hematol Oncol; 2017 Dec; 35(4):875-877. PubMed ID: 27539158
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
13. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
Dada R; Zekri J
J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
[TBL] [Abstract][Full Text] [Related]
14. Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin: a case report.
Shi Y; Li Q; Zhang W; Nan Y; Yang T; Liang X; Xiao C; Guo B; Xiang Y
Ann Palliat Med; 2020 Jul; 9(4):2414-2419. PubMed ID: 32692239
[TBL] [Abstract][Full Text] [Related]
15. Recent treatment advances in Hodgkin lymphoma: a concise review.
Arulogun S; Hertzberg M; Gandhi MK
Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
[TBL] [Abstract][Full Text] [Related]
16. Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide.
Madabhavi IV; Revannasiddaiah S; Sarkar MS; Modi MG
Oral Oncol; 2019 Jun; 93():122-124. PubMed ID: 31010638
[TBL] [Abstract][Full Text] [Related]
17. Immune-related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab.
Tchapyjnikov D; Borst AJ
J Immunother; 2017 Sep; 40(7):286-288. PubMed ID: 28604555
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma.
Serrao A; Canichella M; De Luca ML; Tartaglia G; Annechini G; D'Elia GM; Pulsoni A
Ann Hematol; 2019 Jun; 98(6):1505-1506. PubMed ID: 30413900
[No Abstract] [Full Text] [Related]
19. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
Aslan A; Aras T; Özdemir E
Leuk Lymphoma; 2017 Mar; 58(3):754-755. PubMed ID: 27687237
[No Abstract] [Full Text] [Related]
20. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
